Sanofi-Aventis BSI-201 Phase II setback could be PARP party-pooper
This article was originally published in Scrip
Sanofi-Aventis' PARP inhibitor, BSI-201 (iniparib) has missed its primary endpoints - overall survival after 18 months and progression-free survival in a 12 month timeframe - in its most advanced clinical study with the compound, a phase III trial in around 400 patients with metastatic triple-negative breast cancer. As the most advanced trial of any PARP inhibitor, the result may raise questions for companies such as AstraZeneca, Abbott, and Pfizer, whose PARP inhibitors are in phase II trial for various solid-tumour indications
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.